Exploring the Role of Novel Medical Therapies for Aggressive Pituitary Tumors: A Review of the Literature—“Are We There Yet?”
Aggressive pituitary tumors account for up to 10% of pituitary tumors and are characterized by resistance to medical treatment and multiple recurrences despite standard therapies, including surgery, radiotherapy, and chemotherapy. They are associated with increased morbidity and mortality, particula...
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2020-01-01
|
| Series: | Cancers |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2072-6694/12/2/308 |
| _version_ | 1797724628503756800 |
|---|---|
| author | Lydia S. Lamb Hao-Wen Sim Ann I. McCormack |
| author_facet | Lydia S. Lamb Hao-Wen Sim Ann I. McCormack |
| author_sort | Lydia S. Lamb |
| collection | DOAJ |
| description | Aggressive pituitary tumors account for up to 10% of pituitary tumors and are characterized by resistance to medical treatment and multiple recurrences despite standard therapies, including surgery, radiotherapy, and chemotherapy. They are associated with increased morbidity and mortality, particularly pituitary carcinomas, which have mortality rates of up to 66% at 1 year after diagnosis. Novel targeted therapies under investigation include mammalian target of rapamycin (mTOR), tyrosine kinase, and vascular endothelial growth factor (VEGF) inhibitors. More recently, immune checkpoint inhibitors have been proposed as a potential treatment option for pituitary tumors. An increased understanding of the molecular pathogenesis of aggressive pituitary tumors is required to identify potential biomarkers and therapeutic targets. This review discusses novel approaches to the management of aggressive pituitary tumors and the role of molecular profiling. |
| first_indexed | 2024-03-12T10:19:46Z |
| format | Article |
| id | doaj.art-89337378726d477e8c4184314ffadbc3 |
| institution | Directory Open Access Journal |
| issn | 2072-6694 |
| language | English |
| last_indexed | 2024-03-12T10:19:46Z |
| publishDate | 2020-01-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Cancers |
| spelling | doaj.art-89337378726d477e8c4184314ffadbc32023-09-02T10:15:04ZengMDPI AGCancers2072-66942020-01-0112230810.3390/cancers12020308cancers12020308Exploring the Role of Novel Medical Therapies for Aggressive Pituitary Tumors: A Review of the Literature—“Are We There Yet?”Lydia S. Lamb0Hao-Wen Sim1Ann I. McCormack2Department of Endocrinology, St Vincent’s Hospital, Sydney, NSW 2010, AustraliaGarvan Institute of Medical Research, Sydney, NSW 2010, AustraliaDepartment of Endocrinology, St Vincent’s Hospital, Sydney, NSW 2010, AustraliaAggressive pituitary tumors account for up to 10% of pituitary tumors and are characterized by resistance to medical treatment and multiple recurrences despite standard therapies, including surgery, radiotherapy, and chemotherapy. They are associated with increased morbidity and mortality, particularly pituitary carcinomas, which have mortality rates of up to 66% at 1 year after diagnosis. Novel targeted therapies under investigation include mammalian target of rapamycin (mTOR), tyrosine kinase, and vascular endothelial growth factor (VEGF) inhibitors. More recently, immune checkpoint inhibitors have been proposed as a potential treatment option for pituitary tumors. An increased understanding of the molecular pathogenesis of aggressive pituitary tumors is required to identify potential biomarkers and therapeutic targets. This review discusses novel approaches to the management of aggressive pituitary tumors and the role of molecular profiling.https://www.mdpi.com/2072-6694/12/2/308aggressive pituitary tumorspituitary carcinomamolecular profilingtargeted therapyimmunotherapy |
| spellingShingle | Lydia S. Lamb Hao-Wen Sim Ann I. McCormack Exploring the Role of Novel Medical Therapies for Aggressive Pituitary Tumors: A Review of the Literature—“Are We There Yet?” Cancers aggressive pituitary tumors pituitary carcinoma molecular profiling targeted therapy immunotherapy |
| title | Exploring the Role of Novel Medical Therapies for Aggressive Pituitary Tumors: A Review of the Literature—“Are We There Yet?” |
| title_full | Exploring the Role of Novel Medical Therapies for Aggressive Pituitary Tumors: A Review of the Literature—“Are We There Yet?” |
| title_fullStr | Exploring the Role of Novel Medical Therapies for Aggressive Pituitary Tumors: A Review of the Literature—“Are We There Yet?” |
| title_full_unstemmed | Exploring the Role of Novel Medical Therapies for Aggressive Pituitary Tumors: A Review of the Literature—“Are We There Yet?” |
| title_short | Exploring the Role of Novel Medical Therapies for Aggressive Pituitary Tumors: A Review of the Literature—“Are We There Yet?” |
| title_sort | exploring the role of novel medical therapies for aggressive pituitary tumors a review of the literature are we there yet |
| topic | aggressive pituitary tumors pituitary carcinoma molecular profiling targeted therapy immunotherapy |
| url | https://www.mdpi.com/2072-6694/12/2/308 |
| work_keys_str_mv | AT lydiaslamb exploringtheroleofnovelmedicaltherapiesforaggressivepituitarytumorsareviewoftheliteraturearewethereyet AT haowensim exploringtheroleofnovelmedicaltherapiesforaggressivepituitarytumorsareviewoftheliteraturearewethereyet AT annimccormack exploringtheroleofnovelmedicaltherapiesforaggressivepituitarytumorsareviewoftheliteraturearewethereyet |